Oncology

Atezolizumab being examined as first-line treatment for individuals ineligible for cisplatin chemotherapy.

Combination approach better targets breast cancer tumors with PIK3CA gene mutations.

Top news of the week in oncology and cancer drug development.

Nonsteroidal anti-inflammatory drugs effective in preventing advanced neoplasia recurrence.

Combination therapy may help combat treatment resistance in cancer patients.

Top news of the day from across the health care landscape.

ASN003 is a drug that targets cancers driven by BRAF and PI3K.

ASN003 demonstrated potent action against tumor growth.

Device helps surgeons distinguish between cancerous and non-cancerous tissues.

Treatment with antihypertensive drugs was seen to lower cancer-related proteins.

Top news of the day from across the health care landscape.

Aspirin may serve as a preventive measure for pancreatic cancer development.

The FDA has granted priority review for the supplemental new drug application (sNDA) from Bayer for Stivarga, also known as regorafenib.

Certain hypertension drugs block breast and pancreatic cancer invasion.

Cancer accounts for more years of life lost than any other cause of death.

Cancer accounts for more years of life lost than any other cause of death.

Top articles of the year on Specialty Pharmacy Times.

Association between cancer diagnosis and suicide on a population level suggested.

Top oncology articles of 2016 on Specialty Pharmacy Times.

New cancer-spreading protein discovered in groundbreaking study.

Relapsed or refractory leukemia patients who received CC-486 had a 38% overall response rate.

Breast cancer patients with many social ties have significantly lower rates of death and recurrence.

Nivolumab plus ipilimumab deemed tolerable in non-small cell lung cancer patients, with notable improvements in safety.

Myeloproliferative neoplasms may negatively affect the physical and mental health of patients.

Targeting the KRAS mutation was found successful in a patient with metastatic colorectal cancer.

This year's top oncology articles.

Thioguanine and decitabine combination therapy show positive results in phase 1 trial.

The cause of a rare sarcoma may provide a promising new treatment target for soft tissue cancer.

Patients with serious illness who receive palliative care were more satisfied with their health care.

Study seeks the optimal drug combination for patients with HCV genotype 2 and cirrhosis.